Abstract
We evaluated the effect of erythromycin therapy on pulmonary function tests and the airway inflammatory response of patients with DPB. The number of neutrophils in BALF obtained from DPB patients was significantly higher than that of healthy volunteers. Treatment with erythromycin (600 mg/day for 12·9 ± 9·5 months (mean ±s.d.)) significantly reduced the total number of cells and neutrophils in the airway, and significantly improved pulmonary function tests. The levels of IL-1β and IL-8 were significantly higher in DPB compared with healthy volunteers (P < 0·05, P < 0·05, respectively). IL-1 Ra in patients is considered to have a weak inhibitory activity for IL-1β, with approximately five-fold concentration of IL-1β compared with that in healthy volunteers (approx. nine-fold concentration of IL-1β). Erythromycin therapy significantly reduced these cytokines to levels comparable to those of healthy volunteers, and produced a trend toward reduction in the level of IL-1Ra in BALF. The level of IL-1β correlated significantly with the concentration of neutrophils in BALF (r = 0·72, P < 0·01), as well as with the level of IL-1Ra (r = 0·688, P < 0·05) and IL-8 (r = 0·653, P < 0·05). A nearly significant or significant correlation was observed between the concentration of neutrophils and levels of IL-1Ra or IL-8 in BALF (r = 0·526, P = 0·053 or r = 0·776, P < 0·01, respectively). There was also a significant relationship between FEV, and the concentration of neutrophils in BALF (r = 0·524, P < 0·05). Our results suggest that the relative amounts of IL-1β and IL-1Ra or IL-8 may contribute, at least in part, to the neutrophil-mediated chronic airway inflammation in patients with chronic airway disease, and long-term erythromycin therapy may down-regulate the vigorous cycle between the cytokine network and neutrophil accumulation, with resultant reduction of neutrophil-mediated inflammatory response.
Keywords: IL-1β, IL-1 receptor antagonist, bronchoalveolar lavage, chronic airway disease, diffuse panbronchiolitis
Full Text
The Full Text of this article is available as a PDF (548.7 KB).
References
- 1.Homma H, Yamanaka A, Tanimoto S, et al. Diffuse panbronchiolitis: a disease of the transitional zone of the lung. Chest. 1983;83:63–69. doi: 10.1378/chest.83.1.63. [DOI] [PubMed] [Google Scholar]
- 2.Ichikawa Y, Ninomiya H, Koga H, et al. Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients. Am Rev Respir Dis. 1992;146:196–203. doi: 10.1164/ajrccm/146.1.196. [DOI] [PubMed] [Google Scholar]
- 3.Kadota J, Sakito O, Kohno S, et al. A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. Am Rev Respir Dis. 1993;147:153–9. doi: 10.1164/ajrccm/147.1.153. [DOI] [PubMed] [Google Scholar]
- 4.McElvaney NG, Nakamura H, Birrer P, et al. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surfaces by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest. 1992;90:1296–301. doi: 10.1172/JCI115994. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Richman-Eisenstat JBY, Jorens PG, Hebert CA, Ueki I, Nadel JA. Interleukin-8: an important chemoattractant in sputum of patients with chronic inflammatory airway diseases. Am J Physiol. 1993;264:L413–8. doi: 10.1152/ajplung.1993.264.4.L413. [DOI] [PubMed] [Google Scholar]
- 6.Oishi K, Sonoda F, Kobayashi S, et al. Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases. Infect Immun. 1994;62:4145–52. doi: 10.1128/iai.62.10.4145-4152.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Sakito O, Kadota J, Kohno S, Abe K, Shirai R, Kara K. Interleukin 1β, tumor necrosis factor alpha and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis—a potential mechanism of macrolide therapy. Respiration. doi: 10.1159/000196514. in press. [DOI] [PubMed] [Google Scholar]
- 8.Oppenheim JJ, Zachariae COC, Mukaida N, Matsushima K. Properties of the novel proinflammatory supergene ‘intercline’ cytokine family. Ann Rev Immunol. 1991;9:617–48. doi: 10.1146/annurev.iy.09.040191.003153. [DOI] [PubMed] [Google Scholar]
- 9.Baggiolini M, Walz A, Kunkel SL. Neutrophil-activating peptide-1/ interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest. 1989;84:1045–9. doi: 10.1172/JCI114265. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Ruef C, Jefferson DM, Schlegel-Haueter SE, Suter S. Regulation of cytokine secretion by cystic fibrosis airway epithelial cells. Eur Respir J. 1993;6:1429–36. [PubMed] [Google Scholar]
- 11.Carter DB, Deibel MR, Dunn CJ, et al. Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature. 1990;244:633–8. doi: 10.1038/344633a0. [DOI] [PubMed] [Google Scholar]
- 12.Hannum CH, Wilcox CJ, Arend WP, et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature. 1990;343:336–40. doi: 10.1038/343336a0. [DOI] [PubMed] [Google Scholar]
- 13.Moore SA, Streiter RM, Rolfe MW, Standiford TJ, Burdick MD, Kunkel SL. Expression and regulation of human alveolar macrophage-derived interleukin-1 receptor antagonist. Am J Respir Cell Mol Biol. 1992;6:569–75. doi: 10.1165/ajrcmb/6.6.569. [DOI] [PubMed] [Google Scholar]
- 14.Kline J, Monick M, Hunninghake G. IL-1 receptor antagonist release is regulated differently in human alveolar macrophages than in monocytes. J Appl Physiol. 1992;73:1686–92. doi: 10.1152/jappl.1992.73.4.1686. [DOI] [PubMed] [Google Scholar]
- 15.Arend WP, Joslin FG, Thompson RG, Hannum CH. An IL-1 inhibitor from human monocytes. J Immunol. 1989;143:1851–8. [PubMed] [Google Scholar]
- 16.Chang DM. Cellular signals for the induction of human interleukin-1 receptor antagonist. Clin Immunol Immunopathol. 1995;74:23–30. doi: 10.1006/clin.1995.1004. [DOI] [PubMed] [Google Scholar]
- 17.Goto F, Goto K, Miyata T, et al. Interleukin-1 receptor antagonist in inflammatory exudate cells of rabbits: production, purification and determination of primary structure. Immunology. 1992;77:235–44. [PMC free article] [PubMed] [Google Scholar]
- 18.Dinarello CA, Thompson RC. Blocking IL-1: interleukin-1 receptor antagonist in vivo and in vitro. Immunol Today. 1991;12:404–10. doi: 10.1016/0167-5699(91)90142-G. [DOI] [PubMed] [Google Scholar]
- 19.Kline JN, Schwartz DA, Monick MM, Floerchinger CS, Hunninghake GW. Relative release of interleukin-1β and interleukin-1 receptor antagonist by alveolar macrophages: a study in asbestos-induced lung disease, sarcoidosis, and idiopathic pulmonary fibrosis. Chest. 1993;104:47–53. doi: 10.1378/chest.104.1.47. [DOI] [PubMed] [Google Scholar]
- 20.Nagai S, Takeuchi M, Watanabe K, Aung H, Izumi T. Smoking and interleukin-1 activity released from human alveolar macrophages in healthy subjects. Chest. 1988;94:694–700. doi: 10.1378/chest.94.4.694. [DOI] [PubMed] [Google Scholar]
- 21.Nagai S, Aung H, Takeuchi M, Kusume K, Izumi T. IL-1 and IL-1 inhibitory activity in the culture supernatants of alveolar macrophages from patients with interstitial lung diseases. Chest. 1991;99:674–80. doi: 10.1378/chest.99.3.674. [DOI] [PubMed] [Google Scholar]
- 22.Clapp WD, Becker S, Quay J, et al. Grain dust-induced airflow obstruction and inflammation of the lower respiratory tract. Am J Respir Crit Care Med. 1994;150:611–7. doi: 10.1164/ajrccm.150.3.8087327. [DOI] [PubMed] [Google Scholar]
- 23.Kudoh S, Uetake T, Hagiwara K, et al. Clinical effect of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis. Jpn J Thorac Dis. 1987;25:632–42. [PubMed] [Google Scholar]
- 24.Yamamoto M, Kondo A, Tamura A, Izumi T, Ina Y, Noda M. Long-term therapeutic effects of erythromycin and new quinolone antibacterial agents on diffuse panbronchiolitis. Jpn J Thorac Dis. 1990;28:1305–13. [PubMed] [Google Scholar]
- 25.Annual report on the study of diffuse disseminated lung disease by Yamamoto M. 1991. Grant-in-Aid from the Ministry of Health and Welfare in Japan.
- 26.Thomsen MK, Larsen CG, Thomsen HK, et al. Recombinant human interleukin-8 is a potent activator of canine neutrophil aggregation, migration, and leukotriene B4 biosynthesis. J Invest Dermatol. 1991;96:260–6. doi: 10.1111/1523-1747.ep12464458. [DOI] [PubMed] [Google Scholar]
- 27.Schroder J-M. The monocyte-derived neutrophil activating peptide (NAP/interleukin-8) stimulates human neutrophil arachidonate-5-lipoxygenase, but not the release of cellular arachidonate. J Exp Med. 1989;170:847–63. doi: 10.1084/jem.170.3.847. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.O'Driscoll BRC, Kay AB. Leukotrienes and lung disease. Thorax. 1982;37:241–5. doi: 10.1136/thx.37.4.241. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Zakrzewski JT, Barnes NC, Costello JF, Piper PJ. Lipid mediators in cystic fibrosis and chronic obstructive pulmonary disease. Am Rev Respir Dis. 1987;136:779–82. doi: 10.1164/ajrccm/136.3.779. [DOI] [PubMed] [Google Scholar]
- 30.Lawrence R, Sorrell T. Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet. 1993;342:465–9. doi: 10.1016/0140-6736(93)91594-c. [DOI] [PubMed] [Google Scholar]
- 31.Oda H, Kadota J, Kohno S, Hara K. Leukotriene B4 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. Chest. 1995;108:116–22. doi: 10.1378/chest.108.1.116. [DOI] [PubMed] [Google Scholar]
- 32.Arend WP, Welgus HG, Thompson RC, Eisenberg SP. Biological properties of recombinant human monocyte-derived interleukin-1 receptor antagonist. J Clin Invest. 1990;85:1694–7. doi: 10.1172/JCI114622. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Granowitz EV, Clark BD, Mancilla J, Dinarello CA. Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type 11 interleukin-1 receptor. J Biol Chem. 1991;266:14147–50. [PubMed] [Google Scholar]
- 34.Palma C, Cassone A, Serbousek D, Pearson CA, Djeu JY. Lactoferrin release and interleukin-1, interleukin-6, and tumor necrosis factor production by human polymorphonuclear cells stimulated by various lipopolysaccharides: relationship to growth inhibition of Candida albicans. Infect Immun. 1992;60:4604–11. doi: 10.1128/iai.60.11.4604-4611.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]